IP Library Granted Patent US 11,326,158
Granted Patent B2
US 11,326,158 · App. 16/510,365 · Granted May 10, 2022

Enrichment of cell-free DNA from a biological sample

Inventors: Noah C. Welker (South San Francisco, CA); Clement S. Chu (South San Francisco, CA)
Assignee: Myriad Women's Health, Inc.
C12N15/1013C12Q1/6806
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,326,158
App. No.
16/510,365
Granted
May 10, 2022
Kind
B2
Abstract

Provided are methods and compositions for enriching cfDNA fragments from a biological fluid sample. A biological fluid sample, such as a urine sample, is collected and, in certain examples, pretreated before enrichment of the cfDNA. For the pretreatment, the sample is centrifuged to remove large cells and large cellular debris. As part of the pretreatment, the sample is also cleared of additional large cellular debris and excess volume by subjecting the sample to anion exchange chromatography and eluting bound DNA. Following any pretreatment of the sample, different concentrations an alcoholic solution are used—along with a mixture of DNA-binding particles and a chaotropic agent—to enrich the sample with cfDNA fragments having different sizes. For example, a biological sample can be enriched with small cfDNA fragments less than about 100 base pairs in length or large cfDNA fragments greater than about 100 base pairs in length.

Claims (24)

1. A method for enriching systemic cell-free DNA (cfDNA) fragments from a urine sample, comprising:

contacting a urine sample with a first alcoholic solution, a first chaotropic agent, and a first plurality of DNA-binding particles to form a first reaction solution, wherein the first reaction solution has an alcohol concentration of 35% v/v or less;

separating the first plurality of DNA-binding particles from the first reaction solution, thereby forming a first particle fraction and a first non-particle fraction, wherein the first particle fraction comprises post-glomerular cfDNA fragments;

contacting the first non-particle fraction with a second alcoholic solution and a second plurality of DNA-binding particles to form a second reaction solution, wherein the second reaction solution has an alcohol concentration of at least 55% v/v alcohol;

separating the second plurality of DNA-binding particles from the second reaction solution, thereby forming a second particle fraction and a second non-particle fraction; and

eluting cfDNA fragments from the second plurality of DNA-binding particles of the particle fraction, wherein the eluate is enriched with systemic cfDNA fragments having a length of between about 10 base pairs and 80 base pairs.

2. The method of claim 1 , wherein the first plurality of DNA-binding particles are silica magnetic bead particles and wherein separating the first plurality of silica magnetic bead particles from the first reaction solution comprises subjecting the first reaction solution to a magnetic field.

3. The method of claim 2 , wherein the second plurality of DNA-binding particles are silica magnetic bead particles and wherein separating the second plurality of silica magnetic bead particles from the second reaction solution comprises subjecting the second reaction solution to a magnetic field.

4. The method of claim 1 , wherein the eluate is enriched with cfDNA fragments of about 30 base pairs.

5. The method of claim 1 , wherein the alcohol of the first reaction solution or the second reaction solution is isopropyl alcohol or ethyl alcohol.

6. The method of claim 1 , further comprising contacting the urine sample with a chelating agent before forming the first reaction solution.

7. The method of claim 6 , wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(P-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), or a combination thereof.

8. The method of claim 1 , further comprising, before forming the first reaction solution, subjecting the urine sample to centrifugation, wherein the centrifugation results in a supernatant that is substantially free of whole cells.

9. The method of claim 8 , wherein contacting the urine sample to form the first reaction solution comprises contacting the supernatant that is substantially free of whole cells.

10. The method of claim 8 , further comprising reducing the volume of the supernatant by subjecting the supernatant to ion-exchange chromatography.

11. The method of claim 10 , wherein the volume of the supernatant is reduced to 20 ml or less.

12. The method of claim 10 , wherein the ion-exchange chromatography substantially removes cellular debris from the supernatant, the cellular debris comprising proteins, lipids, subcellular organelles, or combinations thereof.

13. The method of claim 1 , wherein the chaotropic agent is a salt.

14. The method of claim 1 , wherein the chaotropic agent is guanidine thiocyanate and wherein the first reaction solution has a guanidine thiocyanate concentration of at least 2 M guanidine thiocyanate.

15. The method of claim 1 , wherein the chaotropic agent is guanidine thiocyanate and wherein the second reaction solution has a guanidine thiocyanate concentration of at least 2 M guanidine thiocyanate.

16. The method of claim 1 , wherein the eluate is enriched with cfDNA fragments having a length of between about 20 base pairs and 60 base pairs.

17. The method of claim 1 , wherein the eluate is substantially free of DNA greater than 5,000 base pairs in length.

18. The method of claim 1 , wherein the alcohol concentration of the first reaction solution is 25% to 35% v/v.

19. The method of claim 1 , wherein the alcohol concentration of the second reaction solution is 55% to 60% v/v.

Assignments (7)
SECURITY INTEREST Recorded Aug 1, 2025
From: MYRIAD GENETICS, INC.; MYRIAD GENETIC LABORATORIES, INC.; MYRIAD WOMEN’S HEALTH, INC.; ASSUREX HEALTH, INC.; GATEWAY GENOMICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT FOR SECURED PARTIES
Reel/Frame 072309/0932 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (064235/0032) Recorded Aug 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MYRIAD GENETICS, INC.; MYRIAD WOMEN’S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
Reel/Frame 072331/0215 →
RELEASE OF SECURITY INTEREST Recorded Jul 10, 2023
From: JPMORGAN CHASE BANK, N.A.
To: MYRIAD GENETICS, INC.; CRESCENDO BIOSCENCE, INC.; MYRIAD RBM, INC.; MYRIAD WOMEN'S HEALTH, INC.
Reel/Frame 064239/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 7, 2023
From: MYRIAD GENETICS, INC.; MYRIAD WOMEN'S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 064235/0032 →
CHANGE OF NAME Recorded Mar 24, 2022
From: COUNSYL, INC.
To: MYRIAD WOMEN'S HEALTH, INC.
Reel/Frame 059499/0298 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2022
From: WELKER, NOAH C.; CHU, CLEMENT S.
To: COUNSYL, INC.
Reel/Frame 059395/0034 →
SECURITY INTEREST Recorded Sep 15, 2020
From: MYRIAD WOMEN'S HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 053773/0968 →